| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cumberland Pharmaceuticals Inc.$5.93
-0.25 (-4.14%)
C 52Pipeline Score Undervalued Pharma · Commercial
Market Cap
87.95 M
EPS
-0.49
P/E Ratio
-
Value Trade
213.02 K
SEC Financials
Q1 2026Dilution Risk
Revenue
9.13 M
R&D Expenses
1.46 M
Operating CF
387.02 K
Total Assets
71.00 M
Total Liabilities
49.69 M
Equity
21.64 M
D/E Ratio
12,345
22.55 %
Week
89.35 %
1 Month
50.13 %
3 Month
204.15 %
6 Month
95.67 %
5 Year
-65.47 %
All Time
Cash Data
Cash Position
14.85 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
48.63 K
52 Week Range
1.85 - 6.27
% held by Insiders
41.6 %
% held by Institutions
18.43 %
Enterprise Value
86.68 M
Total Shares
15.08 M
Short %
3.87 %
Float Shares
8.76 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cumberland Pharmaceuticals Inc.
756Total events
7Upcoming
279Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 7
Event history 749
Jul 1, 2026
▲AcquiredCorporate
Apotex completes strategic transaction to integrate Cumberland's U.S. branded businesses
Jul 1, 2026
Jul 1, 2026
▲Primary Endpoint MetIfetrobanClinical Data
Breakthrough results in Phase II study of ifetroban for DMD cardiomyopathy
Duchenne Muscular Dystrophy Cardiomyopathysource ↗
Jul 1, 2026
◆FDA Feedback ReceivedIfetrobanFDA Meeting
Interactions with FDA regarding study results and approval requirements
Duchenne Muscular Dystrophy Cardiomyopathysource ↗
Jul 1, 2026
●Enrollment UpdateIfetrobanTrial
Phase II study for IPF actively enrolling
Idiopathic Pulmonary Fibrosissource ↗
Jul 1, 2026
▲Interim AnalysisIfetrobanTrial
Favorable interim safety findings announced for ifetroban in IPF
Idiopathic Pulmonary Fibrosissource ↗
Jul 1, 2026
▲Full ResultsIfetrobanClinical Data
Results of Pilot Study of ifetroban in cancer metastasis announced
Cancer Metastasissource ↗
Jun 26, 2026
▲Poster PresentationIfetrobanPresentation
Updated FIGHT DMD trial results presented at PPMD annual conference
Duchenne muscular dystrophy cardiomyopathysource ↗
Jun 26, 2026
◆Full ResultsIfetrobanClinical Data
Updated results from FIGHT DMD trial including 36-month safety and biomarker data
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
Jun 26, 2026
▲Long Term DataIfetrobanClinical Data
36-month safety data from open-label extension
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
Jun 26, 2026
◆Oral PresentationIfetrobanPresentation
Updated FIGHT DMD trial results presented at PPMD annual conference
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
Jun 26, 2026
▲Biomarker DataIfetrobanClinical Data
Novel blood biomarker results: MYL3, MYOD1, FGF16, TSPAN7
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
Drug Pipeline Intelligence
C52
Pipeline Score $600M
Pipeline ValueUndervalued
Valuation Signal13
Drugs Scored6.8x
rNPV / MCap Top 79%
Micro Cap (rank 192 of 911)
Percentile RankCumberland Pharmaceuticals Inc. carries a moderate pipeline score (52/100), with $2.4B risk-adjusted pipeline value, led by Ifetroban in Malignant Solid Tumor (Phase 2), across $73B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ifetroban Small molecule | Cardiovascular Diseases | Phase 2 | NCT03962855 | 67% | $1.1B | COMPLETED | 57 | - | - | Nov 15, 2022 | - | Dec 5, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ifetroban Fast TrackOrphanRare Pediatric | cancer metastasis prevention | Phase 2a | 2026-06-02 | deaths due to metastasis placebo: 3; deaths due to metastasis ifetroban: 0; distant metastatic recurrence placebo: 50; distant metastatic recurrence ifetroban: 17; p value deaths: 0.037; p value recurrence: 0.091 Read More | Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis Read More | |
ifetroban Fast TrackOrphanRare Pediatric | cancer metastasis prevention | Phase 2a | 2026-06-02 | deaths due to metastasis placebo: 3; deaths due to metastasis ifetroban: 0; distant metastatic recurrence placebo: 50; distant metastatic recurrence ifetroban: 17; p value deaths: 0.037; p value recurrence: 0.091 Read More | Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis Read More | |
ifetroban Fast TrackOrphanRare Pediatric | cancer metastasis prevention | Phase 2a | 2026-06-02 | deaths due to metastasis placebo: 3; deaths due to metastasis ifetroban: 0; distant metastatic recurrence placebo: 50; distant metastatic recurrence ifetroban: 17; p value deaths: 0.037; p value recurrence: 0.091 Read More | Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CPIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CPIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CPIX▲ +10%on this news
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
Apotex Health Corp. has successfully completed a strategic transaction with Cumberland Pharmaceuticals, integrating Cumberland's U.S. branded businesses into its operations. This acquisition enhances Apotex's portfolio with established medicines in areas such as oncology and infectious disease. The leadership of both companies expressed optimism about improving patient care and expanding access to high-quality treatments.
Read more →CPIX▲ +10%on this news
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
Cumberland Pharmaceuticals has completed a $100 million transaction with Apotex, enhancing its focus on rare disease treatments. The agreement, supported by over 99% of shareholders, allows Cumberland to concentrate on developing ifetroban, a drug targeting several serious conditions. The company retains its innovative product portfolio and majority ownership in Cumberland Emerging Technologies.
Read more →CPIX▲ +12.3%on this newsshared move
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals presented updated results from its Phase 2 FIGHT DMD trial at the PPMD conference, showcasing ifetroban's potential in treating cardiac issues associated with Duchenne muscular dystrophy (DMD). The findings highlighted improvements in cardiac function and biomarkers of heart damage, reinforcing the drug's cardioprotective effects. The trial results are significant as they address a critical gap in DMD treatment options.
Read more →CPIXCumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
Cumberland Pharmaceuticals and Vanderbilt Health announced positive results from a Phase 2a clinical trial of ifetroban, aimed at preventing cancer metastasis in high-risk solid tumor patients. The trial met its primary endpoint for safety and showed promising efficacy, with fewer deaths due to metastasis in the ifetroban group compared to placebo. These findings support the continued development of ifetroban as a potential therapy for metastasis prevention.
Read more →CPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
Cumberland Pharmaceuticals has launched its antibiotic Vibativ (telavancin) in China through a partnership with SciClone Pharmaceuticals. This launch follows regulatory approval from China's National Medical Products Administration, allowing SciClone to promote and distribute the drug in a significant pharmaceutical market. Vibativ is designed to treat serious bacterial infections, including those caused by resistant strains.
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS COMPANY UPDATE Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical ne
Cumberland Pharmaceuticals reported its Q1 2026 financial results, including net revenues of $9.1 million, representing a 5% increase from the previous year. The company has entered a strategic transaction with Apotex to sell its portfolio of FDA-approved brands for $100 million, aiming to refocus on high-value product candidates. Notably, the company received Fast Track Designation for its promising product ifetroban, aimed at treating Duchenne muscular dystrophy. Despite these advances, Cumberland posted a net loss of $3.3 million for the quarter.
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. reported a 5% increase in net revenues to $9.1 million for Q1 2026, alongside a strategic transaction with Apotex to enhance its focus on high-value product candidates. The company is advancing its pipeline, particularly the ifetroban candidate, which has received Fast Track Designation from the FDA. Despite these positive developments, Cumberland reported a net loss of $3.3 million for the quarter.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will announce its Q1 2026 financial results on May 5, 2026. The announcement will be followed by a conference call at 4:30 p.m. ET to discuss the results and provide a company update. Cumberland focuses on specialty pharmaceuticals, particularly in acute care, gastroenterology, and oncology.
Read more →CPIXRedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
RedHill Biopharma reported its full-year 2025 financial results, highlighting a transformative year marked by strategic partnerships, particularly with Cumberland Pharmaceuticals for Talicia. The company expanded its market reach and received positive FDA feedback for RHB-204, while also facing increased operating losses. Despite these challenges, RedHill ended the year with improved equity and significant revenue from licensing agreements.
Read more →CPIX▲ +27.9%on this newsshared move
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
Cumberland Pharmaceuticals has announced a strategic agreement with Apotex to integrate their branded U.S. businesses. The deal, valued at $100 million, will allow Cumberland to focus on its pipeline of orphan drug candidates while Apotex aims to enhance patient care. The transaction is pending shareholder approval.
Read more →CPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
Cumberland Pharmaceuticals has received FDA approval for an expanded indication of its Caldolor® (ibuprofen) Injection, now including postoperative pain management. This approval is accompanied by the launch of a new website aimed at healthcare professionals, emphasizing non-opioid pain management strategies. The updated labeling positions Caldolor as a versatile option for both adult and pediatric patients.
Read more →CPIXCumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
Cumberland Pharmaceuticals has launched a new website for its Sancuso® product, aimed at providing educational resources related to chemotherapy-induced nausea and vomiting (CINV). The site offers comprehensive product information, healthcare provider resources, and patient education. Sancuso is the only FDA-approved transdermal patch for CINV prevention, delivering medication for up to five days.
Read more →CPIX▼ -19.9%on this news
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland Pharmaceuticals reported a 31% increase in fourth-quarter revenue for 2025, totaling $13.7 million. The company achieved an 18% increase in annual revenue, reaching $44.5 million. Highlights include successful international product launches, positive clinical trial results for ifetroban in DMD, and the establishment of a permanent reimbursement code for Caldolor. Despite a net loss, the company shows strong growth potential.
Read more →CPIX▼ -5.4%on this news· ran to -28% by day 3shared move
Document CUMBERLAND PHARMACEUTICALS REPORTS 31.1% FOURTH QUARTER 2025 REVENUE GROWTH Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn. (Tuesday
Cumberland Pharmaceuticals Inc. reported a 31.1% increase in fourth quarter 2025 revenue, totaling $13.7 million. The company achieved full-year net revenues of $44.5 million, up 18% from the prior year, alongside a reduced net loss of $2.9 million. Key highlights include substantial international expansion, new product approvals, and successful clinical trial results for the drug ifetroban, targeted for Duchenne muscular dystrophy. Additionally, Caldolor's new permanent J-code is expected to enhance its accessibility in clinical settings.
Read more →CPIXCUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
Cumberland Pharmaceuticals has launched a national sales promotion for Talicia®, an FDA-approved treatment for H. pylori infections. This initiative follows a co-commercialization agreement with RedHill Biopharma and aims to enhance prescription growth. Talicia is recognized as a first-line treatment and is patent protected until 2042, positioning it favorably in the market.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will announce its 2025 financial results on March 3, 2026, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results and provide a company update. The company focuses on developing products for acute care, gastroenterology, and oncology.
Read more →CPIXCumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
Cumberland Pharmaceuticals has received FDA Fast Track Designation for its oral therapy ifetroban, aimed at treating heart disease in Duchenne muscular dystrophy (DMD) patients. This designation allows for expedited development and review, following positive Phase 2 trial results that demonstrated a significant improvement in heart function. The company aims to address the urgent medical needs of DMD patients with this therapy.
Read more →CPIXDocument Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program NASHVILLE, Tenn. (
Cumberland Pharmaceuticals announced that its ifetroban program for Duchenne muscular dystrophy (DMD) heart disease has received Fast Track Designation from the FDA. This designation aims to expedite the development and review process for drugs addressing serious medical conditions. Recent Phase 2 trial results showed a significant improvement in heart function in DMD patients. The Fast Track status allows Cumberland to interact more frequently with the FDA, enhancing the potential for quicker access to this much-needed therapy.
Read more →CPIX▼ -9.2%on this news
CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
Cumberland Pharmaceuticals announced that its Caldolor® (ibuprofen) Injection has received a permanent J-code (J1741) associated with a reimbursement price. This development supports healthcare providers in offering a non-opioid option for pain management, aligning with opioid-sparing initiatives. The update aims to improve patient care and reduce reliance on opioids.
Read more →CPIX▼ -12.4%on this news· ran to -26% by day 3
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
Cumberland Pharmaceuticals reported a 12% increase in year-to-date revenues, totaling $30.8 million. The company has successfully added Talicia to its product portfolio and launched Vibativ in Saudi Arabia. Despite these positive developments, Cumberland recorded a net loss of approximately $1.4 million for the year so far, highlighting ongoing financial challenges.
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH NASHVILLE, Tenn. (
Cumberland Pharmaceuticals has announced a 12% increase in year-to-date revenues, reaching $30.8 million. The company attributes this growth to its FDA-approved product portfolio and the recent addition of Talicia to its commercial offerings. Despite the positive revenue figures, Cumberland reported a net loss of approximately $1.4 million for the year, highlighting ongoing operational expenses. Additionally, their product candidate ifetroban is displaying notable efficacy in clinical trials for treating Duchenne muscular dystrophy.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will release its third quarter 2025 financial results on November 4, 2025, and hold a conference call to discuss these results and provide a company update. The company specializes in pharmaceutical products for hospital acute care, gastroenterology, and oncology. Cumberland's portfolio includes several FDA-approved medications and ongoing Phase II clinical programs for various medical conditions. This announcement reflects Cumberland's ongoing commitment to transparency and shareholder engagement.
Read more →CPIXCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
Cumberland Pharmaceuticals has entered a strategic partnership with RedHill Biopharma to co-commercialize Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infections. This collaboration will involve forming a new company where both parties will share revenues and operational responsibilities. Talicia has shown a strong clinical profile with a high eradication rate and is included as a first-line treatment in current clinical guidelines. The product is patent-protected until 2042 and has substantial insurance coverage, further bolstering its market position.
Read more →CPIXCUMBERLAND PHARMACEUTICALS
Cumberland Pharmaceuticals Inc. announced that its antibiotic Vibativ has been included in a national purchasing agreement with Premier, Inc., effective October 1, 2025. This agreement expands access to Vibativ for thousands of healthcare providers and hospitals in the U.S., allowing for flexible ordering options. The addition of a 4-vial Starter Pak aims to provide a more cost-effective alternative for initiating therapy in diverse clinical settings. Vibativ is designed to combat difficult-to-treat Gram-positive infections, maintaining its efficacy against drug-resistant strains.
Read more →CPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
Cumberland Pharmaceuticals has received regulatory approval for its injectable ibuprofen product in Mexico, in partnership with PiSA Farmaceutica. This product aims to provide effective non-opioid pain management in hospital settings. The approval reflects the growing demand for alternatives to opioids and underscores the strength of the collaboration between Cumberland and PiSA.
Read more →CPIXTABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
Cumberland Pharmaceuticals and Tabuk Pharmaceutical Manufacturing have launched Vibativ® (telavancin) in Saudi Arabia, an FDA-approved antibiotic for serious infections. This partnership grants Tabuk exclusive rights to promote the drug in the region, addressing the urgent need for effective treatments against multidrug-resistant bacteria. Vibativ is designed to treat hospital-acquired pneumonia and complicated skin infections.
Read more →CPIX▼ -5.5%on this news· ran to -20% by day 1
Document Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date NASHVILLE, Tenn. (Tuesday
Cumberland Pharmaceuticals reported a 23% increase in year-to-date revenues, totaling $22.6 million through the first half of 2025. The company's product portfolio delivered a combined net revenue of $10.8 million in the second quarter, showcasing growth compared to the prior year. CEO A.J. Kazimi expressed optimism for continued success, emphasizing the importance of ongoing clinical development programs. Recent developments include the availability of Vibativ through Vizient and promising results from ifetroban studies targeting Duchenne muscular dystrophy.
Read more →CPIX▼ -5.5%on this news· ran to -20% by day 1
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
Cumberland Pharmaceuticals reported substantial revenue growth of 23% for the first half of 2025, totaling $22.6 million. The second quarter also showed a 10% revenue increase year-on-year. Key developments include the launch of the Vibativ 4-Vial Starter Pak through Vizient and promising findings from the Phase II FIGHT DMD trial on ifetroban. Despite these successes, the company recorded a net loss in the latest quarter, highlighting ongoing financial challenges.
Read more →CPIXCUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
Cumberland Pharmaceuticals has secured a contract with Vizient, enhancing the availability of its Vibativ 4-Vial Starter Pak. This contract allows Vizient members, which include a significant portion of acute care providers, to access this antibiotic for treating serious infections. The new configuration aims to facilitate treatment in both inpatient and outpatient settings.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will announce its second quarter 2025 financial results and provide a company update on August 5, 2025. A conference call is scheduled for the same day at 4:30 p.m. ET, where participants can register to join. The company is also involved in Phase II clinical programs for various conditions.
Read more →CPIX▼ -9.7%on this news· ran to -38% by day 3
Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals presented encouraging results from its Phase 2 FIGHT DMD trial at the Parent Project Muscular Dystrophy conference, indicating ifetroban's potential in treating heart disease associated with Duchenne muscular dystrophy (DMD). The trial showed a significant improvement in left ventricular ejection fraction and a reduction in markers of cardiac damage among patients treated with ifetroban. The findings underscore the importance of targeted therapies for DMD heart disease, which is a leading cause of death in affected patients. Following this positive data, Cumberland intends to engage with the FDA regarding future regulatory steps.
Read more →CPIX▲ +5.1%on this news
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS
Cumberland Pharmaceuticals Inc. announced positive results from a study on Caldolor4 (intravenous ibuprofen) for pain management in older patients. The study found a significant reduction in the need for opioids, indicating Caldolor's effectiveness in managing pain and fever in patients aged 60 and older. The safety profile of Caldolor was favorable, with lower adverse event rates compared to placebo. This advancement emphasizes the potential for Caldolor as a key component in multimodal analgesia, especially for the aging population.
Read more →CPIX▲ +5.5%on this news
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland Pharmaceuticals has entered a partnership with Qureight to enhance its Phase II FIGHTING FIBROSIS clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Utilizing Qureight's deep-learning image analytics, the collaboration aims to provide deeper insights into treatment efficacy and disease progression for ifetroban, a candidate drug for IPF. This initiative addresses the urgent need for more effective treatments for the estimated 2 million patients worldwide with limited options. Both organizations are set to showcase their collaborative efforts at the upcoming American Thoracic Society International Conference.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 NASHVILLE, Tenn. (Tuesday
Cumberland Pharmaceuticals Inc. reported a significant 38% revenue growth for Q1 2025, amounting to $11.7 million. The company's CEO expressed optimism about ongoing clinical programs, particularly in Duchenne muscular dystrophy (DMD), where recent Phase II results were positively received. Additionally, the antibiotic Vibativ has been approved in China, marking an important milestone for the company. Cumberland's strong performance indicates solid financial health with a net profit of $1.3 million for the quarter.
Read more →CPIXCumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
Cumberland Pharmaceuticals Inc. reported a significant revenue growth of 38% in Q1 2025, generating net revenues of $11.7 million and a net profit of $1.3 million. The company announced positive Phase II study results for its ifetroban product candidate in treating Duchenne muscular dystrophy, marking a breakthrough in addressing cardiac complications. Additionally, the antibiotic Vibativ received approval in China, paving the way for its launch in the second-largest pharmaceutical market. Cumberland emphasizes its ongoing momentum and potential for strategic acquisitions and partnerships.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will announce its first quarter 2025 financial results and provide a company update on May 6, 2025. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time, allowing stakeholders to discuss the results. The company specializes in unique pharmaceutical products for acute care, gastroenterology, and oncology, and has ongoing clinical programs for new treatments.
Read more →CPIXFIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference
Cumberland Pharmaceuticals announced that results from its Phase 2 FIGHT DMD clinical trial regarding ifetroban utilization in treating cardiac issues related to Duchenne muscular dystrophy (DMD) have been selected for a late-breaking presentation at the MDA Clinical & Scientific Conference. The study revealed a significant 5.4% improvement in left ventricular ejection fraction compared to placebo, highlighting the potential for improved patient outcomes. Company leadership expressed optimism regarding the impact of these findings on the DMD community, given the ongoing challenges of managing cardiac health in DMD patients. Ifetroban holds Orphan Drug and Rare Pediatric Disease designations from the FDA, underlining its potential significance.
Read more →CPIX▲ +17.7%on this news· ran to +32% by day 1
Document Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth 2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2
Cumberland Pharmaceuticals reported an 11.6% increase in net revenues for Q4 2024, totaling $10.4 million. Highlights for the year included FDA approvals and designations for their ifetroban product candidate, along with significant progress in clinical studies and international market expansion. Despite these successes, the company reported a net loss of about $1.9 million for the quarter, raising concerns about financial sustainability. Overall, 2024 was marked as a transformative year for the firm, setting the stage for future growth in 2025.
Read more →CPIX▲ +17.7%on this news· ran to +32% by day 1
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth
Cumberland Pharmaceuticals reported an 11.6% increase in revenue for Q4 2024, totaling $10.4 million, and a full-year revenue of $38 million. The company achieved significant milestones, including FDA Orphan Drug Designations for ifetroban and the successful completion of a Phase II study for treating cardiomyopathy in Duchenne muscular dystrophy. Additionally, Vibativ received approval in China's pharmaceutical market. Despite these advances, Cumberland reported a net loss of approximately $1.9 million for the fourth quarter.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. will announce its annual 2024 financial results on March 4, 2025, after market close. A conference call will follow at 4:30 p.m. ET, where participants can engage via registration. The company is known for its diverse portfolio of FDA-approved products and is also conducting Phase II clinical trials for its ifetroban product candidate aimed at treating multiple conditions.
Read more →CPIX▼ -6.4%on this news· ran to +20% by day 1
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Cumberland Pharmaceuticals' Vibativ (telavancin) injection has received marketing approval from the National Medical Products Administration (NMPA) in China. This approval allows SciClone Pharmaceuticals to exclusively register, promote, and distribute the antibiotic, which is vital for treating pneumonia and serious skin infections caused by drug-resistant bacteria. With a launch planned later this year, Vibativ is positioned as an important drug in combating challenging infections in a rapidly growing market. The partnership aims to ensure that this life-saving treatment reaches as many patients as possible in China.
Read more →CPIX▲ +76.5%on this news· ran to +138% by day 1
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Cumberland Pharmaceuticals reported positive top-line results from the Phase 2 FIGHT DMD trial, evaluating ifetroban for treating heart disease associated with Duchenne muscular dystrophy (DMD). The trial showed a notable improvement in cardiac function, particularly in patients receiving a high dose of ifetroban, marking a significant advancement in addressing an unmet medical need. If approved, ifetroban could become the first therapy specifically for DMD-related heart disease. The results have garnered optimism within the DMD community for better management of this devastating condition.
Read more →CPIXFDA APPROVES ACETADOTE® sNDA
Cumberland Pharmaceuticals Inc. announced FDA approval for a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection). This approval introduces a simplified intravenous (IV) dosing regimen, enhancing the administration of the drug used to combat acetaminophen poisoning. The streamlined approach is designed to minimize medication errors and reduce the incidence of non-allergic anaphylactoid reactions, thereby improving patient outcomes. Cumberland’s leadership expressed optimism about the impact of this development on patient care and healthcare efficiency.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - New Real World Study of 150,000 Patients Favors Caldolor over ketorolac - - DMD Program Receives FDA Orphan Drug Rare
Cumberland Pharmaceuticals announced its financial results for Q3 2024, reporting revenues of $9.1 million and a net loss of $1.5 million. Notable developments include a supportive study showing Caldolor's superiority over ketorolac, and the granting of FDA Orphan Drug and Rare Pediatric Disease Designations for its DMD program. Additionally, the company is expanding Medicaid coverage for Kristalose and advancing its innovative therapies through its Emerging Technologies program. Despite the losses, the optimistic outlook reflects ongoing commitment to improving patient care and addressing unmet medical needs.
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Cumberland Pharmaceuticals reported its third quarter 2024 financial results, revealing revenues of $9.1 million and a net loss of $1.5 million. The company highlighted significant developments, including new research favoring its product Caldolor over ketorolac and receiving FDA Orphan Drug and Rare Pediatric Disease designations for its ifetroban candidate. Additionally, Cumberland expanded Medicaid coverage for Kristalose and provided updates on various ongoing clinical programs and international partnerships. The developments indicate a focus on innovative treatments and potential market growth.
Read more →CPIXCUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Cumberland Pharmaceuticals announced that the FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for treating cardiomyopathy related to Duchenne muscular dystrophy (DMD). This designation aims to expedite the development of effective therapies for this rare genetic disorder, which predominantly affects young boys. The company is currently conducting the FIGHT DMD trial, which is a Phase II study analyzing the safety and efficacy of Ifetroban. Positive results from this trial could pave the way for significant advancements in treatment options for DMD patients.
Read more →CPIXNew Study Compares Caldolor® (ibuprofen injection) to ketorolac
Cumberland Pharmaceuticals announced a study showing that Caldolor (ibuprofen injection) is safer and improves healthcare resource utilization compared to ketorolac in both adults and children. The research indicates a significant reduction in adverse drug reactions and a decrease in hospital visits and lengths of stay. Caldolor demonstrated notable advantages including reduced renal dysfunction, hematuria rates, and gastrointestinal complications. These findings may lead to improved patient care and potential cost savings for the healthcare system.
Read more →CPIX▼ -5.9%on this newsshared move
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. has announced that it will release its third quarter 2024 financial results on November 7, 2024, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss the outcomes, and registration is required for participation. The company, which specializes in acute care pharmaceuticals, continues to develop products for various medical markets, along with ongoing Phase II clinical programs for its ifetroban candidate.
Read more →CPIX▲ +6.4%on this news
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
Cumberland Pharmaceuticals has reported a significant 16% sequential increase in net revenue, amounting to $9.9 million for the second quarter of 2024. This positive performance is bolstered by Medicaid coverage for their product Kristalose in Wisconsin and recommendations from the American Gastroenterological Association. Additionally, a study has highlighted Vibativ's effectiveness against anthrax, reinforcing the company's portfolio. Cumberland's leadership expresses optimism regarding ongoing developments that could contribute to substantial revenue growth throughout the year.
Read more →CPIX▲ +6.4%on this news
Document Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 NASHVILLE, TENNESSEE ( Tuesday
Cumberland Pharmaceuticals reported a 16% sequential revenue growth in Q2 2024, equaling $9.9 million. The increase reflects improved financial performance, highlighted by an adjusted earnings rise to $0.2 million. The company has made significant advancements, including Kristalose's recent inclusion in Medicaid formularies and promising research on Vibativ for anthrax treatment. Additionally, ongoing clinical studies for ifetroban may open new avenues for addressing unmet medical needs in rare diseases.
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update
Cumberland Pharmaceuticals Inc. announced its financial results for the first quarter of 2024, reporting revenue of $8.5 million and a net loss of $1.9 million. The CEO expressed optimism despite external market challenges, highlighting advancements in their product pipeline, specifically Caldolor's favorable clinical data in pain management. The company is preparing for potential Medicare reimbursement for non-opioid pain management under the NOPAIN Act, which could enhance future revenue. Additionally, Cumberland continues to support its products like Sancuso and Vaprisol and push forward with their clinical development programs.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results Company Update NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals reported its financial results for the first quarter of 2024, with revenues reaching $8.5 million amidst various operational challenges. The company highlighted its expanding portfolio, particularly the recognition of Caldolor as a key treatment option for pain management. Notably, efforts are ongoing to secure special Medicare reimbursement for Caldolor under the NOPAIN Act. However, Cumberland also faced a net loss of $1.9 million this quarter, leading to concerns about its financial health in a challenging market environment.
Read more →CPIX▼ -5.6%on this news· ran to -16% by day 1
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. will announce its first quarter 2024 financial results on May 7, 2024, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and updates. Participants can register for the call and will have the option to join via phone or automatic call. The company continues to advance its clinical programs alongside its portfolio of FDA-approved brands, reflecting a focus on enhancing patient care.
Read more →CPIXNEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
Cumberland Pharmaceuticals has released a Special Report endorsing its Caldolor product, which is intravenous ibuprofen, as an effective standard treatment for pain and fever in children and adults. The report highlights significant safety and efficacy findings, emphasizing its potential to reduce opioid dependency in pain management. Caldolor's effectiveness extends to various treatment scenarios including surgical and acute pain relief. The endorsement by clinical experts positions Caldolor as a key player in evolving pain management protocols during the ongoing opioid crisis.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports Annual 2023 Financial Results 2023 highlights include expanded FDA approval and new study publications NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals announced its annual financial results for 2023, showcasing combined revenues of $40 million and a net loss of $6.3 million. Significant achievements included expanded FDA approval for Caldolor, now authorized for infants, and positive clinical study results for Vibativ in pediatric patients. Despite the losses, the company demonstrated a focus on enhancing patient care through new product developments and a newly updated mission statement. Cumberland is actively progressing its pipeline, including innovative products for various unmet medical needs.
Read more →CPIXCumberland Pharmaceuticals Reports Annual 2023 Financial Results
Cumberland Pharmaceuticals Inc. reported its annual financial results for 2023, highlighting a revenue of $40 million and a net loss of $6.3 million. The company successfully expanded the FDA approval of its Caldolor product for infants while publishing supportive clinical study results for Vibativ. Cumberland initiated multiple Phase II clinical trials for its ifetroban candidate, addressing unmet medical needs in conditions like cardiomyopathy and systemic sclerosis. The company also refined its mission statement to emphasize patient-centric care and sustainable practices.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. will announce its annual financial results for 2023 on March 5, 2024, after market close. The company will hold a conference call at 4:30 p.m. ET on the same day to discuss these results. Alongside their financial update, Cumberland is actively involved in developing various products for acute care and has received FDA clearance for a Phase II study focused on Idiopathic Pulmonary Fibrosis.
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
Cumberland Pharmaceuticals Inc. reported third quarter 2023 financial results, revealing revenue of $10.1 million and a net loss of $1.0 million. Notable developments include a new publication on Vibativ's pediatric use and a newly secured credit facility for expansion. The company maintains a strong asset position with $88 million in total assets. Cumberland's ongoing clinical programs for ifetroban aim to address unmet medical needs in rare disorders, despite current operational challenges.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals Inc. reported its financial results for Q3 2023, achieving revenues of $10.1 million and maintaining a year-to-date income of $15,086. Despite a net loss of $1.0 million for the quarter, the company highlighted advancements in its product offerings, including a significant publication related to Vibativ for pediatric use. Looking forward, Cumberland anticipates eligibility for Medicare reimbursement for its Caldolor product, driven by the recently enacted NOPAIN Act. Notably, the firm continues its strategic clinical efforts for its ifetroban product candidate in various rare diseases.
Read more →CPIXCumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
Cumberland Pharmaceuticals Inc. reported strong financial growth for Q2 2023, with revenues of $10.9 million, a 6% increase year-over-year. The company posted a net income of $1.1 million for the first half of the year and positive earnings for the second consecutive quarter. Notably, Cumberland received FDA approval for expanded use of Caldolor® in infants, enhancing its product offerings. The company also reported significant liabilities, highlighting ongoing financial challenges despite positive developments in revenue and income.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals Inc. reported strong financial results for the second quarter of 2023, with revenues of $10.9 million, marking a 6% increase from last year. The company achieved positive net income for the second consecutive quarter, totaling $1.1 million for the first half of the year. Cumberland's recent FDA approval for expanded use of its Caldolor product in infants is a significant milestone, positioning the company for future growth. Overall, the company experienced several key developments, including ongoing clinical studies for its ifetroban product candidate.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. announced it will release its second quarter 2023 financial results on August 8, 2023, followed by a conference call to discuss the outcomes. The company focuses on specialty pharmaceuticals and has FDA-approved products in various medical sectors. Additionally, Cumberland is engaged in multiple Phase II clinical programs, including trials for idiopathic pulmonary fibrosis and cardiomyopathy related to Duchenne Muscular Dystrophy.
Read more →CPIXNEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
Cumberland Pharmaceuticals Inc. announced a publication confirming positive clinical trial results for Caldolor® in newborns. The study, published in Pediatric Drugs, evaluated the drug's safety and pharmacokinetics in infants aged 1 to 6 months. Following the positive findings, the FDA recently approved Caldolor for use in infants, highlighting its potential to treat pain and fever effectively. The study included data from 24 hospitalized infants, showing no adverse effects from the medication.
Read more →CPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
Cumberland Pharmaceuticals announced the FDA's clearance of their Investigational New Drug Application for a Phase II study of ifetroban in treating Idiopathic Pulmonary Fibrosis (IPF). This new clinical program will enroll 128 patients across over 20 U.S. medical centers and aims to evaluate the safety, tolerability, and efficacy of the drug. Ifetroban has shown promise in preclinical studies for its potential to prevent lung fibrosis. Cumberland has previously secured IND approvals for other indications, and they emphasize the importance of developing new treatments for unmet medical needs.
Read more →CPIX▲ +9.1%on this news
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS
Cumberland Pharmaceuticals Inc. has received FDA approval to expand the labeling of Caldolor, allowing its use in treating pain and fever in infants aged 3 to 6 months. This approval highlights Caldolor as the only available injectable non-opioid option for such young patients. A multi-center study supported the product's safety and efficacy for pediatric use. The company also anticipates potential Medicare reimbursement under the NOPAIN Act for this non-opioid treatment, further enhancing its market value.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results Company Update NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals reported financial results for the first quarter of 2023, with revenues of $9.2 million and a net income of $0.2 million. The company expects its Caldolor product to benefit from special Medicare reimbursement under the recent NOPAIN Act. Additionally, Cumberland received an FDA waiver that provides a refund of nearly $2 million for previous fees. The relocation of its headquarters to Nashville aims to connect better with the local healthcare community.
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update
Cumberland Pharmaceuticals Inc. reported a net income of $0.2 million for the first quarter of 2023, with total revenues of $9.2 million driven by its established product portfolio. The company highlighted several strategic developments, including an expected Medicare reimbursement for its Caldolor product under the NOPAIN Act, and a $2 million refund from the FDA following the granting of a waiver. Additionally, Cumberland is advancing multiple clinical programs featuring ifetroban targeting serious medical conditions. The firm remains focused on delivering quality medicines amid a challenging operating environment.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (CPIX) announced it will release its first quarter 2023 financial results on May 9, 2023, after market close. A conference call will follow the announcement to discuss the results and updates regarding the company. Cumberland focuses on developing high-quality prescription brands for the acute care, gastroenterology, and oncology markets, and currently has ongoing Phase II clinical programs for its ifetroban candidate targeting various medical conditions.
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 2022 highlights include its acquisition of Sancuso and move to new headquarters NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals announced a 17% increase in net revenues for 2022, totaling $42 million. The company successfully acquired Sancuso and moved to a new headquarters in Nashville to enhance collaboration and growth. Despite the positive financial performance, Cumberland reported a net loss for the fourth quarter and experienced rising operating expenses during the year. The company continues to advance its clinical programs and expand its portfolio in oncology and other therapeutic areas.
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022
Cumberland Pharmaceuticals Inc. reported a 17% increase in net revenues for the fiscal year 2022, reaching $42 million, despite facing external challenges. The company highlighted significant milestones, including the acquisition of Sancuso, which supports oncology patients, and the relocation to a new headquarters aimed at facilitating growth. Adjusted earnings improved to $2.1 million compared to a loss of $1.2 million in 2021. However, Cumberland also reported a net loss for the year, raising concerns about long-term profitability amidst increasing operating expenses.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will announce its annual 2022 financial results on March 7, 2023, after market hours. A conference call is scheduled for the same day to discuss the results, which will be accessible to registered participants. The company is notable for its portfolio of FDA-approved pharmaceuticals aimed at various medical conditions, including treatments for pain, infection, and gastrointestinal disorders. Additionally, Cumberland has several Phase II clinical programs for its ifetroban candidate related to serious health issues.
Read more →CPIXDocument Cumberland Pharmaceuticals Reports 41% Revenue Growth Company Also Delivers Growing Cash Flow from Operations NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals Reports 41% Revenue Growth Company Also Delivers Growing Cash Flow from Operations NASHVILLE, TENNESSEE (Tuesday, November 8, 2022) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company, announced today that its product p
Read more →CPIXCumberland Pharmaceuticals Reports 41% Revenue Growth
Company Also Delivers Growing Cash Flow from Operations NASHVILLE, Tenn., Nov. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenue
Read more →CPIXCUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST
NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), the largest, public biopharmaceutical company founded and headquartered in Tennessee, announced today that it has moved its headquarters to the Broadwest campus in the Vanderbilt/West E
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8
Read more →CPIXCumberland Pharmaceuticals Reports 14% Revenue Growth
Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn., Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered c
Read more →CPIXDocument Cumberland Pharmaceuticals Reports 14% Revenue Growth Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals Reports 14% Revenue Growth Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, TENNESSEE (Tuesday, August 9, 2022) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company today announced that i
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
The company's annual sustainability report highlights its continued focus on and commitment to environmental, social and governance issues NASHVILLE, Tenn., Aug. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today rel
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug.
Read more →CPIX▲ +10.3%on this news
CUMBERLAND PHARMACEUTICALS APPOINTS MARTIN BROWN JR. TO ITS BOARD OF DIRECTORS
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors o
Read more →CPIXCumberland Pharmaceuticals Reports 6% Revenue Growth
The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, Tenn., May 10, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced that the Compan
Read more →CPIXDocument Cumberland Pharmaceuticals Reports 6% Revenue Growth The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, TENNESSEE (Tuesday
Cumberland Pharmaceuticals Reports 6% Revenue Growth The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, TENNESSEE (Tuesday, May 10, 2022) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty
Read more →CPIX▲ +8.7%on this newsshared move
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
Verity Pharmaceuticals will feature Sancuso across the U.S. through its established oncology commercial organization and customer network NASHVILLE, Tenn. , May 9, 2022 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced toda
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2022 FINANCIAL RESULTS
NASHVILLE, Tenn., May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10
Read more →CPIX▲ +8.5%on this news
TABUK AND CUMBERLAND PARTNER TO BRING INNOVATIVE ANTIBIOTIC WITH LIFE-SAVING POTENTIAL TO MIDDLE EAST
Vibativ® treats patients with multidrug-resistant infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, March 31, 2022 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), headquartered in Nashville, and Tabuk Pharmaceutical Manufact
Read more →CPIX▼ -8.1%on this news
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a company update. Net revenues totaled $36 million, resulting in $6 million in cash flo
Read more →CPIX▼ -8.1%on this news
Document CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS COMPANY UPDATE 2021 highlights include agreement to acquire Sancuso and FDA approval for Caldolor administration prior to surgery NASHVILLE, TENNESSEE (T
CUMBERLAND PHARMACEUTICALS REPORTS 2021 FINANCIAL RESULTS COMPANY UPDATE 2021 highlights include agreement to acquire Sancuso and FDA approval for Caldolor administration prior to surgery NASHVILLE, TENNESSEE (Tuesday, March 8, 2022) - Cumberland Pharmaceuticals Inc. (NASDAQ
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2021 FINANCIAL RESULTS
NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results and provide a company update after the market closes on Tuesday, March 8, 2022.
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO FROM KYOWA KIRIN NORTH AMERICA Nashville-based pharmaceutical company will acquire U.S. rights from Japan-based Kyowa Kirin SANCUSO is an established, FDA-Approved Onc
CUMBERLAND PHARMACEUTICALS ACQUIRES SANCUSO FROM KYOWA KIRIN NORTH AMERICA Nashville-based pharmaceutical company will acquire U.S. rights from Japan-based Kyowa Kirin SANCUSO is an established, FDA-Approved Oncology Supportive Care Medicine NASHVILLE, Tennessee and BEDMINSTE
Read more →CPIXCaldolor® Now FDA Approved For Pre-Operative Administration
NASHVILLE, Tenn., Nov. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of i
Read more →CPIXDocument CALDOLOR NOW FDA APPROVED FOR PRE-OPERATIVE ADMINISTRATION Dosed prior to surgery, Caldolor demonstrated significant reduction in pain intensity NASHVILLE, Tennessee (Monday
CALDOLOR NOW FDA APPROVED FOR PRE-OPERATIVE ADMINISTRATION Dosed prior to surgery, Caldolor demonstrated significant reduction in pain intensity NASHVILLE, Tennessee (Monday, November 29, 2021) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company
Read more →CPIXDocument
Cumberland Pharmaceuticals Moving Corporate Headquarters to Broadwest NASHVILLE, Tennessee - Broadwest is pleased to announce it has entered into an agreement with Cumberland Pharmaceuticals Inc. to relocate the company's corporate offices to the Broadwest campus in the West End
Read more →CPIX▲ +6%on this news
Cumberland Pharmaceuticals Reports Third Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., Nov. 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2021 financial results. Net revenues from continuing operations during the quarter were $8.1 mi
Read more →CPIX▲ +6%on this news
Document CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS COMPANY UPDATE NASHVILLE, Tennessee (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS COMPANY UPDATE NASHVILLE, Tennessee (Tuesday, November 9, 2021) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 202
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2021 Financial Results
NASHVILLE, Tenn., Nov. 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021. A conference call and live in
Read more →CPIXCumberland Pharmaceuticals Launches RediTrex® Product Line For Active Rheumatoid, Juvenile Idiopathic And Severe Psoriatic Arthritis
NASHVILLE, Tenn., Sept. 29, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today the national launch of its RediTrex® (methotrexate) line of pre-filled syringes designed for the safe and simple treatment of activ
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter were $9.1
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS COMPANY UPDATE Year-to-date net revenues up 9.3% NASHVILLE, Tennessee (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS COMPANY UPDATE Year-to-date net revenues up 9.3% NASHVILLE, Tennessee (Tuesday, August 10, 2021) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company, today is providing a c
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2021 Financial Results
NASHVILLE, Tenn., Aug. 3, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021. A conference call and live in
Read more →CPIXCumberland Pharmaceuticals Reports 2.5M Patient Doses Delivered, No Product Recalls, No FDA Issues in 2020
NASHVILLE, Tenn., July 26, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its 2020 Sustainability Report, which details the company's activities pertaining to environmental, social and governance (ESG) matte
Read more →CPIXVibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients
NASHVILLE, Tenn., June 21, 2021 /PRNewswire/ --Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ® (telavancin) in treating secondary bacterial infections in COVID-19
Read more →CPIXCumberland Pharmaceuticals Names John Hamm New Chief Financial Officer
NASHVILLE, Tenn., May 19, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it has promoted John Hamm to Director Finance & Accounting and Chief Financial Officer. In this role, he will manage all of Cumb
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS COMPANY UPDATE NASHVILLE, Tennessee (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS COMPANY UPDATE NASHVILLE, Tennessee (Tuesday, May 11, 2021) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 fi
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2021 Financial Results & Company Update
NASHVILLE, Tenn., May 11, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and first quarter 2021 financial results. Net revenues from continuing operations during the quarter were $10.5 m
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2021 Financial Results
NASHVILLE, Tenn., May 4, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2021 financial results and Company update after the market closes on Tuesday, May 11, 2021. A conference call and live internet webcast
Read more →CPIXCumberland Pharmaceuticals Reports 9% Revenue Growth In 2020
NASHVILLE, Tenn., March 9, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced fourth quarter and full year 2020 financial results. Net Revenues
Read more →CPIXDocument CUMBERLAND PHARMACEUTICALS REPORTS 9% REVENUE GROWTH IN 2020 NASHVILLE, TENNESSEE (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS 9% REVENUE GROWTH IN 2020 NASHVILLE, TENNESSEE (Tuesday, March 9, 2021) - Cumberland Pharmaceuticals Inc. (NASDAQ CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology and rheumatology, today announced four
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2020 Financial Results
NASHVILLE, Tenn., March 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2020 financial results and Company update after the market closes on Tuesday, Mar. 9, 2021. A conference call and live int
Read more →CPIXIntroducing RediTrex®, A New Methotrexate Delivery System
NASHVILLE, Tenn., Nov. 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announced today the launch of RediTrex® (methotrexate) injection. RediTrex is a new line of pre-filled syringes specifically designed for ease
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2020 Financial Results & Company Update
NASHVILLE, Tenn., Nov. 10, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today is providing a company update and third quarter 2020 financial results. Net revenues from continuing operations during the quarter were $9.3 m
Read more →CPIXThis press release may contain statements that are "forward-looking" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, Tennessee (Tuesday, November 10, 2020) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today is providing a company update and third quarter
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2020 Financial Results
NASHVILLE, Tenn., Nov. 3, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2020 financial results and Company update after the market closes on Tuesday, Nov. 10, 2020. A conference call and live internet webcas
Read more →CPIXNewly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use
NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clini
Read more →CPIXIn April 2020, Cumberland released its inaugural Sustainability Report.
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, TN (Tuesday, August 11, 2020) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today prov
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2020 Financial Results & Company Update
NASHVILLE, Tenn., Aug. 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today provided a company update and announced second quarter 2020 financial results. Net revenue
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2020 Financial Results
NASHVILLE, Tenn., Aug. 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2020 financial results and Company update after the market closes on Tuesday, Aug. 11, 2020. A conference call and live internet webca
Read more →CPIXCaldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients
NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demonstrate Caldolor® (
Read more →CPIXNEW PUBLICATION REVEALS REAL-WORLD USAGE
NEW PUBLICATION REVEALS REAL-WORLD USAGE OF VIBATIV IN PATIENTS WITH BACTEREMIA OR ENDOCARDITIS NASHVILLE, Tenn. (Tuesday, May 26 2020) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World
Read more →CPIXNew Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
NASHVILLE, Tenn., May 26, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with ba
Read more →CPIXIn April 2020, Cumberland released its first Sustainability Report.
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS & COMPANY UPDATE NASHVILLE, TN (Wednesday, May 20, 2020) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provid
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2020 Financial Results & Company Update
NASHVILLE, Tenn., May 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today provided a company update and announced first quarter 2020 financial results. Net revenues f
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2020 Financial Results
NASHVILLE, Tenn., May 15, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company update after the market closes on Wednesday, May 20, 2020. A conference call and live Internet web
Read more →CPIXVibativ® Sustained Potency Confirmed In Two Surveillance Studies
NASHVILLE, Tenn., May 11, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces two new publications detailing the sustained in vitro potency of Vibativ® (telavancin) as part of a 7-year antimicrobial surveillance p
Read more →CPIXCumberland Pharmaceuticals Releases Inaugural Report On Its Environmental, Social And Governance (ESG) Activities
NASHVILLE, Tenn., April 28, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released its first Sustainability Report. This report describes the company's activities pertaining to Environmental, Social and Governance (
Read more →CPIXTo Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units
NASHVILLE, Tenn., April 7, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced an initiative to increase availability of Vaprisol® (conivaptan hydrochloride) injection for treating hyponatremia, associated with c
Read more →CPIXCumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections
NASHVILLE, Tenn., March 31, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced a national initiative to support hospitals and clinics that use Caldolor® (ibuprofen) injection for the treatment of patients with f
Read more →CPIXCumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
NASHVILLE, Tenn., March 23, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company, today announced a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associat
Read more →CPIXCumberland Pharmaceuticals Reports 17% Revenue Growth For The Full Year 2019
NASHVILLE, Tenn., March 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and full year 2019 financial results. Net Revenues for the fourt
Read more →CPIXFourth Quarter and Annual Highlights:
CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR THE FULL YEAR 2019 - Received FDA approval for RediTrexTM - Completed Caldolor pediatric study in newborns - Initiated new ifetroban clinical program NASHVILLE, TENNESSEE (Wednesday, March 18, 2020) - Cumberland Pharm
Read more →CPIXCaldolor® Demonstrates Favorable Safety Profile In Newborns
NASHVILLE, Tenn., March 17, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced topline results from a clinical study evaluating the safety and pharmacokinetics of Caldolor® (ibuprofen) Injection in children ranging from birth to six months of age.
Read more →CPIXCumberland Pharmaceuticals Reschedules Fourth Quarter And Annual 2019 Financial Results
NASHVILLE, Tenn., March 6, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today the rescheduling of its fourth quarter and annual 2019 financial results and company update from Wednesday, March 11, 2020 to Wednesday, March 18, 2020 after market clos
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results
NASHVILLE, Tenn., March 4, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2019 financial results and company update after the market closes on Wednesday, March 11, 2020. A conference call and live
Read more →CPIXCumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product
NASHVILLE, Tenn., Jan. 7, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company with a focus on hospital acute care, today announced the launch of Caldolor® (ibuprofen) Injection in a ready-to-use bag that may be administered with
Read more →CPIXCumberland Pharmaceuticals To Hold Update Call To Discuss Recent Major Developments
NASHVILLE, Tenn., Jan. 2, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will hold an update call to discuss recent developments and plans for the Company's Caldolor® and RediTrexTM brands after the market closes on Tuesday, January 7,
Read more →CPIXCumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line
NASHVILLE, Tenn., Dec. 2, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for RediTrex™, its new line of methotrexate products.
Read more →CPIXNew Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
NASHVILLE, Tenn., Nov. 25, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new online publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes that resulted from treating multiple
Read more →CPIXNEW STUDY REVEALS REAL-WORLD USAGE
NEW STUDY REVEALS REAL-WORLD USAGE OF VIBATIV IN A VARIETY OF INFECTIONS NASHVILLE, Tenn. (Monday, November 25, 2019) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new online publication in Drugs - Real World Outcomes, det
Read more →CPIXCumberland Pharmaceuticals Reports 22% Revenue Growth In The Third Quarter
NASHVILLE, Tenn., Nov. 12, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced third quarter 2019 financial results with net revenues of $10.4 million, up 22% o
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2019 Financial Results
NASHVILLE, Tenn., Nov. 5, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2019 financial results after the market closes on Tuesday, November 12, 2019. A conference call and live Internet webcast will be held
Read more →CPIXNEW STUDY REVEALS SUPERIORITY OF VIBATIV
NEW STUDY REVEALS SUPERIORITY OF VIBATIV OVER VANCOMYCIN IN SELECT PATIENTS WITH BACTERIAL PNEUMONIA NASHVILLE, Tenn. (Tuesday, October 15, 2019) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious
Read more →CPIXNew Study Reveals Superiority Of Vibativ® Over Vancomycin In Select Patients With Bacterial Pneumonia
NASHVILLE, Tenn., Oct. 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announces a new publication in Infectious Diseases and Therapy, showing numerically superior cure rates of telavancin compared to vancomycin wit
Read more →CPIXCumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program
NASHVILLE, Tenn., Sept. 24, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced FDA Orphan Drug Grant funding for a new Phase II clinical program. The Company has initiated the clinical development of ifetroban
Read more →CPIXThis release contains forward-looking statements within the meaning of the federal securities laws, which are subject to certain risks and reflect Cumberland's current views on fut
CUMBERLAND PHARMACEUTICALS REPORTS 14% REVENUE GROWTH IN THE SECOND QUARTER NASHVILLE, TN (Wednesday, August 14, 2019) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced second
Read more →CPIXCumberland Pharmaceuticals Reports 14% Revenue Growth In The Second Quarter
NASHVILLE, Tenn., Aug. 14, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology today announced second quarter 2019 financial results with net revenues of $11.6 million, up 14%
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2019 Financial Results
NASHVILLE, Tenn., Aug. 7, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2019 financial results after the market closes on Wednesday, August 14, 2019. A conference call and live Internet webcast will be held
Read more →CPIXCumberland Pharmaceuticals Signs Exclusive Licensing Agreement For Distribution In China
NASHVILLE, Tenn., May 15, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced it has entered into an exclusive agreement with China's Winhealth Pharma Group for the licensing rights of Acetadote® (acetylcysteine
Read more →CPIXCumberland Pharmaceuticals Reports 38% Revenue Growth In The First Quarter
NASHVILLE, Tenn., May 14, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced first quarter 2019 financial results with net revenues
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results
NASHVILLE, Tenn., May 7, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2019 financial results after the market closes on Tuesday, May 14, 2019. A conference call and live Internet webcast will be held on Tue
Read more →CPIXCumberland Pharmaceuticals Announces Strategic Review
NASHVILLE, Tenn., March 29, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that it has commenced a strategic review of its branded product portfolio, as well as its roster of international partners. The Com
Read more →CPIXCumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%
NASHVILLE, Tenn., Feb. 26, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care, today announced fourth quarter and full year 2018 financial results.
Read more →CPIXFourth Quarter Highlights:
CUMBERLAND PHARMACEUTICALS REPORTS FOURTH QUARTER REVENUE GROWTH OF 16% - Acquired Vibativ from Theravance Biopharma - Closed largest product transaction in Company's history - Acquisition funded by $20 million credit line expansion NASHVILLE, TENNESSEE (Tuesday, February 26
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results
NASHVILLE, Tenn., Feb. 19, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2018 financial results after the market closes on Tuesday, February 26, 2019. A conference call and live Internet webcast
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results
NASHVILLE, Tenn., Nov. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2018 financial results and Company updat
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2018 Financial Results
NASHVILLE, Tenn., Nov. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2018 financial results after the market closes on Tuesday, November 13, 2018. A conference call and live Internet webcast will be held
Read more →CPIXCumberland Pharmaceuticals To Acquire VIBATIV®
NASHVILLE, Tenn., Nov. 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a definitive agreement to acquire VIBATIV® from Theravance Biopharma. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focus
Read more →CPIXNewly Published Data Demonstrates Amifostine Delayed The Onset Of Acute Esophagitis For Small Cell Lung Cancer Patients
NASHVILLE, Tenn., Sept. 27, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, announce a new publication in Lung Cancer: Targ
Read more →CPIXCumberland Pharmaceuticals Announces Senior Music Industry Executive Joins Its Board Of Directors
NASHVILLE, Tenn., Sept. 24, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announced that Joe Galante, music industry executive, has joined its Board of Directors. He is the former Chairman of Sony Music in Nashville and President of RCA Records
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2018 Financial Results
NASHVILLE, Tenn., Aug. 14, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced second quarter 2018 financial results and Company upda
Read more →CPIXCumberland Pharmaceuticals Appoints New Senior Executive
NASHVILLE, Tenn., Aug. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX) today announced the appointment of biopharmaceutical industry veteran Adam Haeberle, Ph.D. as senior director, clinical and regulatory affairs. His responsibilities will include overseeing C
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2018 Financial Results
NASHVILLE, Tenn., Aug. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2018 financial results after the market closes on Tuesday, August 14, 2018. A conference call and live Internet webcast will be held o
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2018 Financial Results
NASHVILLE, Tenn., May 8, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced first quarter 2018 financial results. Net revenues for t
Read more →CPIXQ1 2018 EARNINGS RELEASE Exhibit CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS - Caldolor sNDA accepted by the FDA - Advancing four Phase II clinical programs NASHVILLE, TN (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS - Caldolor sNDA accepted by the FDA - Advancing four Phase II clinical programs NASHVILLE, TN (Tuesday, May 8, 2018) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company fo
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2018 Financial Results
NASHVILLE, Tenn., May 1, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2018 financial results after the market closes on Tuesday, May 8, 2018. A conference call and live Internet webcast will be held on Tues
Read more →CPIXNewly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria
NASHVILLE, Tenn., March 26, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company announced today the publication of an open access article in Infection and Drug Resistance, with results demonstrating an 85% eradication rate
Read more →CPIXQ4 EARNINGS RELEASE Exhibit CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017 - National sales and distribution of Totect initiated - New Data on Caldolor and Vaprisol published - Co-promotion
CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017 - National sales and distribution of Totect initiated - New Data on Caldolor and Vaprisol published - Co-promotion for Kristalose launched NASHVILLE, TN (Tuesday, March 6, 2018) - Cumberland Pharmac
Read more →CPIXCumberland Pharmaceuticals Reports 25% Revenue Growth For The Full Year 2017
NASHVILLE, Tenn., March 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced fourth quarter and full year 2017 financial results. N
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2017 Financial Results
NASHVILLE, Tenn., Feb. 27, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2017 financial results after the market closes on Tuesday, March 6, 2018. A conference call and live Internet webcast will
Read more →CPIXNewly Published Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients
Cumberland Pharmaceuticals Logo (PRNewsfoto/Cumberland Pharmaceuticals Inc.) Clinigen logo (PRNewsfoto/Cumberland Pharmaceuticals) NASHVILLE, Tenn., Jan. 30, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinige
Read more →CPIXEARNINGS RELEASE Q3 2017 Exhibit CUMBERLAND PHARMACEUTICAL REPORTS 27% REVENUE GROWTH IN THE THIRD QUARTER - Launched Totect in the United States - Implemented Kristalose Co-Promotion Agreement NASHVILLE, TN (Tuesday, No
CUMBERLAND PHARMACEUTICAL REPORTS 27% REVENUE GROWTH IN THE THIRD QUARTER - Launched Totect in the United States - Implemented Kristalose Co-Promotion Agreement NASHVILLE, TN (Tuesday, November 7th, 2017) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceu
Read more →CPIXCumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter
NASHVILLE, Tenn., Nov. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced third quarter 2017 financial results with Net Revenues
Read more →CPIXCumberland Pharmaceuticals to Announce Third Quarter 2017 Financial Results
NASHVILLE, Tenn., Oct. 31, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2017 financial results after the market closes on Tuesday, November 7, 2017. A conference call and live Internet webcast will be held
Read more →CPIXCumberland Pharmaceuticals Launches Promotion of Totect® in The U.S. for Emergency Oncology Intervention
NASHVILLE, Tenn. and BURTON ON TRENT, England, Sept. 25, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX, 'Cumberland') and Clinigen Group plc (AIM:CLIN, 'Clinigen'), announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S. Tot
Read more →CPIXQ2 2017 EARNINGS RELEASE Exhibit CUMBERLAND PHARMACEUTICAL REPORTS DOUBLE DIGIT REVENUE GROWTH FOR THE FOURTH CONSECUTIVE QUARTER - Revenues Grew 17% Over the Prior Year Period - New Co-Promotion Agreement for Kristalose
CUMBERLAND PHARMACEUTICAL REPORTS DOUBLE DIGIT REVENUE GROWTH FOR THE FOURTH CONSECUTIVE QUARTER - Revenues Grew 17% Over the Prior Year Period - New Co-Promotion Agreement for Kristalose added NASHVILLE, TN (Tuesday, August 8, 2017) - Cumberland Pharmaceuticals Inc. (NASDAQ:
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results
NASHVILLE, Tenn., Aug. 1, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2017 financial results after the market closes on Tuesday, August 8, 2017. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Pharmaceuticals Begin U.S. Shipments Of Dexrazoxane For Oncology Patient Support
NASHVILLE, Tenn., July 31, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing dexrazoxane, sold under the brand na
Read more →CPIXCumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017
NASHVILLE, Tenn., May 15, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2017 financial results with Net Revenues of $9.6 million and Adjust
Read more →CPIXEARNINGS RELEASE Q1 Exhibit CUMBERLAND PHARMACEUTICALS REPORTS REVENUE GROWTH OF 25% IN FIRST QUARTER 2017 - Acquired exclusive U.S. Rights to Totect - Successfully defended Acetadote patent NASHVILLE, TN (Monday
CUMBERLAND PHARMACEUTICALS REPORTS REVENUE GROWTH OF 25% IN FIRST QUARTER 2017 - Acquired exclusive U.S. Rights to Totect - Successfully defended Acetadote patent NASHVILLE, TN (Monday, May 15, 2017) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical
Read more →CPIXCumberland Pharmaceuticals to Announce First Quarter 2017 Financial Results
NASHVILLE, Tenn., May 8, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2017 financial results after the market closes on Monday, May 15, 2017. A conference call and live Internet webcast will be held on Mond
Read more →CPIXNew Kristalose® Growth Driver Established Through Co-Promotion Agreement
NASHVILLE, Tenn., April 26, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Poly Pharmaceuticals Inc., a privately-held U.S. specialty pharmaceutical company, have entered into a co-promotion partnership for Kristalose®
Read more →CPIXCaldolor® Demonstrates Significant Post Surgical Pain Reduction and Decrease in Opioid Use
NASHVILLE, Tenn., March 27, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a trial providing evidence that using Caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in pa
Read more →CPIXQ4 EARNINGS RELEASE Exhibit CUMBERLAND PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS - Caldolor launched for use in children - National promotion of Ethyol initiated - Two new development pr
CUMBERLAND PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS - Caldolor launched for use in children - National promotion of Ethyol initiated - Two new development programs added NASHVILLE, TN (Tuesday, March 7, 2017) - Cumberland Pharmaceuticals In
Read more →CPIXCumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results
NASHVILLE, Tenn., March 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and full year 2016 financial results. Net Revenues for the year e
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2016 Financial Results
NASHVILLE, Tenn., Feb. 28, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2016 financial results after the market closes on Tuesday, March 7, 2017. A conference call and live Internet webcast will
Read more →CPIXCaldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics
NASHVILLE, Tenn., Feb. 7, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of a multicenter clinical study demonstrating that Caldolor® (ibuprofen) Injection delivered significant fever reduction in hospitalized children. This st
Read more →CPIXU.S. Court Of Appeals Affirms Cumberland Pharmaceuticals
NASHVILLE, Tenn., Jan. 30, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced that on January 26, 2017, the U.S. Court of Appeals for the Federal Circuit rule
Read more →CPIXCumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors
NASHVILLE, Tenn., Jan. 16, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is pleased to announce the addition of Kenneth J. Krogulski, CFA to its Board of Directors. He is the President and Chief Executive Officer of Berkshire Asset Management LLC. He is also
Read more →CPIXCumberland Pharmaceuticals and Clinigen Enter Exclusive U.S. Commercialization Agreement For Totect®
NASHVILLE, Tenn., Jan. 9, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical and services company, announce an exclusive agreement to commercialize
Read more →CPIXCumberland Pharmaceuticals Acquires U.S. Rights to Nordic Group
NASHVILLE, Tenn., Nov. 16, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX), a U.S. specialty pharmaceutical company has entered into an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.'s innovative injectable methotrexate product line. The produc
Read more →CPIXEARNINGS RELEASE Exhibit CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER & YEAR TO DATE 2016 FINANCIAL RESULTS - Launched Ethyol in the United States - New Portaban TM Development Program Initiated - Revenues up 11% Ove
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER & YEAR TO DATE 2016 FINANCIAL RESULTS - Launched Ethyol in the United States - New PortabanTM Development Program Initiated - Revenues up 11% Over Prior Year Period NASHVILLE, TN (Tuesday, November 1, 2016) - Cumberland Pharm
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2016 Financial Results
NASHVILLE, Tenn., Oct. 25, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2016 financial results after the market closes on Tuesday, November 1, 2016. A conference call and live Internet webcast will be held
Read more →CPIXCumberland Pharmaceuticals Launches Promotion Of Ethyol® In The United States For Oncology Patient Support
NASHVILLE, Tenn., Sept. 26, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), announced today that it has launched the U.S. promotion of Ethyol® (amifostine) for Injection, a hospital-based product used to treat oncology patients. Ethyol is an FDA approved cyto
Read more →CPIXCumberland Pharmaceuticals Announces New Program To Develop Portaban™ For Portal Hypertension
NASHVILLE, Tenn., Sept. 14, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), today announced the initiation of a new Phase II clinical program of Portaban™ for patients with portal hypertension associated with liver disease. The U.S. Food and Drug Administratio
Read more →CPIXCumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support
NASHVILLE, Tenn., Aug. 23, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results
NASHVILLE, Tenn., Aug. 2, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2016 financial results with Net Revenues of $7.4 million and Adjus
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS - Entered into Commercialization Agreement for Ethyol - Development Program for VasculanTM Initiated NASHVILLE, TN (Tuesday, August 2, 2016) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2016 Financial Results
NASHVILLE, Tenn., July 26, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release second quarter 2016 financial results after the market closes on Tuesday, August 2, 2016. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Pharmaceuticals To Participate In Avondale Partners
NASHVILLE, Tenn., July 18, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations today announced that management will participate in the 4th A
Read more →CPIXCumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors
NASHVILLE, Tenn., June 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is pleased to announce the addition of Caroline Young to its Board of Directors. Caroline is the prior President of the Nashville Health Care Council and founding Executive Director of t
Read more →CPIXSEC Exhibit CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Caldolor Launched for Use in Pediatric Patients - Co-Promotion Underway to Support Hospital Products NASHVILLE, TN (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2016 FINANCIAL RESULTS - Caldolor Launched for Use in Pediatric Patients - Co-Promotion Underway to Support Hospital Products NASHVILLE, TN (Tuesday, May 10, 2016) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty p
Read more →CPIXCumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement for oncology support drug Ethyol®
NASHVILLE, Tenn., May 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. ('Cumberland', NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc ('Clinigen', AIM: CLIN), the global pharmaceutical and services company, have signed an exclusive agreement
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2016 Financial Results
NASHVILLE, Tenn., May 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2016 financial results with Net Revenues of $7.7 million and Adjust
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results
NASHVILLE, Tenn., May 3, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016. A conference call and live Internet webcast will be held on Tue
Read more →CPIXCumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis
NASHVILLE, Tenn., April 27, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, announced today the addition of VASCULANTM to its pipeline.
Read more →CPIXCaldolor® Launched For The Treatment Of Pain And Fever In Children
NASHVILLE, Tenn., March 24, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) a specialty pharmaceutical company, today announced the launch of Caldolor® (ibuprofen) injection for pediatric patients. This launch follows the U.S. Food and Drug Administration (FDA)
Read more →CPIXCumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results
Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.) NASHVILLE, Tenn., March 3, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fo
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2015 Financial Results
Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.) NASHVILLE, Tenn., Feb. 25, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2015 financial results after the market clos
Read more →CPIXVaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics
Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.) NASHVILLE, Tenn., Feb. 10, 2016 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of an open label multicenter study adding to the growing body of literature
Read more →CPIXPiramal Critical Care And Cumberland Pharmaceuticals Announce Launch Of Caldolor And Vaprisol Co-Promotion
Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.) BETHLEHEM, Pa. and NASHVILLE, Tenn., Jan. 25, 2016 /PRNewswire/ -- Piramal Critical Care, an integral business unit of Piramal Enterprises Limited (NSE: PEL, BSE: 500302), and Cumberland Pharmaceuticals
Read more →CPIXCaldolor® Launched In Australia For Treatment Of Pain And Fever
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn., Nov. 23, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals (NASDAQ: CPIX) announced today the launch of Caldolor® in Australia. Caldolor is an intravenous formulation of ibuprofen, approved by Therapeutic Goods Administration (TGA)
Read more →CPIXCaldolor Approved For Use In Pediatric Patients
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn., Nov. 23, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology announced the approval of Caldolor® (ibuprofen) Injection for ped
Read more →CPIXCumberland Pharmaceuticals Announces Favorable Acetadote® Patent Ruling
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn., Nov. 20, 2015 /PRNewswire/ -- On November 17, 2015, an Illinois judge issued a final ruling in favor of Cumberland Pharmaceuticals Inc. in a patent case associated with its Acetadote® product. Cumberland (NASDAQ:CPIX) is a specia
Read more →CPIXCumberland Pharmaceuticals And Piramal Enterprises Announce Co-Promotion Agreement
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn. and BETHLEHEM, Pa., Nov. 6, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, and Piramal Critical Care, an integral busines
Read more →CPIXHepatoren and Boxaban Phase II Clinical Studies Complete
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER & YEAR TO DATE 2015 FINANCIAL RESULTS - Hepatoren and Boxaban Phase II Clinical Studies Complete - Entered into Strategic Alliance with Clinigen Group plc - Integrated Safety Analysis Published Supporting the Safety of Caldolo
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter & Year To Date 2015 Financial Results
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn., Nov. 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2015 financial results with Net Re
Read more →CPIXNew Caldolor Integrated Safety Analysis Published Supporting The Safety Of Caldolor® (ibuprofen) Injection
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn., Oct. 27, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of an integrated safety analysis adding to the growing body of literature that support the safety of Caldolor® (ibuprofe
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2015 Financial Results
Cumberland Pharmaceuticals Logo NASHVILLE, Tenn., Oct. 27, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2015 financial results after the market closes on Tuesday, November 3, 2015. A conference call and liv
Read more →CPIXCumberland Pharmaceuticals and Clinigen Group Announce Strategic Alliance
NASHVILLE, Tenn., Sept. 17, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, has agreed to a strategic alliance with Clinigen Group plc (AIM: CLIN), the global pharmaceutic
Read more →CPIXQ2 2015 - ex 99.1 earnings release CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER & YEAR TO DATE 2015 FINANCIAL RESULTS - Hepatoren and Boxaban Clinical Studies Enrollment Progressing - sNDA for Caldolor Pediatric Lab
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER & YEAR TO DATE 2015 FINANCIAL RESULTS - Hepatoren and Boxaban Clinical Studies Enrollment Progressing - sNDA for Caldolor Pediatric Label Update Advances NASHVILLE, TN (Tuesday, August 4, 2015) - Cumberland Pharmaceuticals In
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results
NASHVILLE, Tenn., July 28, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release second quarter 2015 financial results after the market closes on Tuesday, August 4, 2015. A conference call and live Internet webcast will be held o
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2015 Financial Results
NASHVILLE, Tenn., May 7, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2015 financial results with Adjusted Earnings up 72% to $1.6 million
Read more →CPIXQ1 2015 - ex 99.1 earnings release CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Caldolor sNDA submitted and accepted for review by FDA - Phase II clinical trial for Boxaban enrollment progres
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS - Caldolor sNDA submitted and accepted for review by FDA - Phase II clinical trial for Boxaban enrollment progressing - Favorable top line data from Hepatoren study NASHVILLE, TN (Thursday, May 7, 2015)
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2015 Financial Results
NASHVILLE, Tenn., April 30, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2015 financial results after the market closes on Thursday, May 7, 2015. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Pharmaceuticals Announces Return To Growth And Profitability In 2014
NASHVILLE, Tenn., March 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2014 financial results. The Company's revenue grew 15%
Read more →CPIXCumberland Pharmaceuticals Reports Clinical And Regulatory Milestones
NASHVILLE, Tenn., March 3, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced achievement of several clinical and regulatory milestones. These developments in
Read more →CPIXEarnings release CUMBERLAND PHARMACEUTICALS ANNOUNCES RETURN TO GROWTH AND PROFITABILITY IN 2014 - Net revenues up 15% compared to 2013 - Adjusted Earnings of $6.3 million , or $0.35 per share NASHVILLE, TN (Tuesday
CUMBERLAND PHARMACEUTICALS ANNOUNCES RETURN TO GROWTH AND PROFITABILITY IN 2014 - Net revenues up 15% compared to 2013 - Adjusted Earnings of $6.3 million, or $0.35 per share NASHVILLE, TN (Tuesday, March 3, 2015) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty
Read more →CPIXclinical CUMBERLAND PHARMACEUTICALS REPORTS CLINICAL AND REGUALTORY MILESTONES - Initial Hepatoren Phase II study results - sNDA filed with pediatric data for Caldolor - Phase II Boxaban trial underway NA
CUMBERLAND PHARMACEUTICALS REPORTS CLINICAL AND REGUALTORY MILESTONES - Initial Hepatoren Phase II study results - sNDA filed with pediatric data for Caldolor - Phase II Boxaban trial underway NASHVILLE, TN (Tuesday, March 3, 2015) - Cumberland Pharmaceuticals Inc. (NASDAQ:
Read more →CPIXCumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2014 Financial Results
NASHVILLE, Tenn., Feb. 24, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release fourth quarter and annual 2014 financial results after the market closes on Tuesday, March 3, 2015. A conference call and live Internet webcast will
Read more →CPIXCumberland Pharmaceuticals Announces Pipeline Expansion With Boxaban™ (ifetroban) Oral Capsule
NASHVILLE, Tenn., Feb. 11, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban™ (ifetroban) oral capsule for the tre
Read more →CPIXPhase IV Studies Published Supporting The Safety Of A Shortened Infusion Time Of Caldolor® (ibuprofen) Injection
NASHVILLE, Tenn., Feb. 2, 2015 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of two Phase IV studies adding to the growing body of literature that support the tolerability and efficacy of a shortened infusion time of Caldolor® (ibu
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2014 Financial Results
NASHVILLE, Tenn., Nov. 4, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2014 financial results. Cumberland Pharmaceuticals Logo SUMMARY F
Read more →CPIXEARNINGS RELEASE Q3 2014 - ex 99.1 earnings release CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS - Revenues up nearly 50% from prior year period NASHVILLE, TN (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS - Revenues up nearly 50% from prior year period NASHVILLE, TN (Tuesday, November 4, 2014) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2014 Financial Results On November 4, 2014
NASHVILLE, Tenn., Oct. 21, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2014 financial results after the market closes on Tuesday, November 4, 2014. A conference call and live Internet webcast will be held o
Read more →CPIXCaldolor® Safely Treats Fever In Hospitalized Children
NASHVILLE, Tenn., Oct. 14, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that treatment with intravenous ibuprofen was superior in reducing temperatures in hospitalized, febrile pediatric patients when compared to treatment with oral or suppo
Read more →CPIXCaldolor® Provides Favorable Inflammatory Response Results In Laparoscopic Cholecystectomy Surgery Patients
NASHVILLE, Tenn., Oct. 10, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that preoperative intravenous ibuprofen improved overall quality of recovery in patients undergoing laparoscopic cholecystectomy surgery. These results will be presented
Read more →CPIXEARNINGS RELEASE Q2 2014 - ex 99.1 earnings release CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Revenues Up 38% from prior year period - New line of credit established with SunTrust Bank NA
CUMBERLAND PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS - Revenues Up 38% from prior year period - New line of credit established with SunTrust Bank NASHVILLE, TN (Tuesday, August 5, 2014) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmace
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2014 Financial Results
NASHVILLE, Tenn., Aug. 5, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2014 financial results. Cumberland Pharmaceuticals Logo (PRNewsFo
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014
NASHVILLE, Tenn., July 22, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release second quarter 2014 financial results after the market closes on Tuesday, August 5, 2014. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2014 Financial Results
NASHVILLE, Tenn., May 13, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2014 financial results. During the quarter the Company returned to
Read more →CPIXEARNINGS RELEASE Q1 2014 - ex 99.1 earnings release CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS - Launched promotional efforts to support Omeclamox -Pak - Acquired and launched promotion of Va
CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS - Launched promotional efforts to support Omeclamox -Pak - Acquired and launched promotion of Vaprisol - Joint R&D investment with Gloria Pharmaceuticals NASHVILLE, TN (Tuesday, May 13, 2014) - Cumberlan
Read more →CPIXCET investment FOR IMMEDIATE DISTRIBUTION CUMBERLAND PHARMACEUTICALS AND GLORIA PHARMACEUTICALS ANNOUNCE JOINT RESEARCH & DEVELOPMENT INVESTMENT NASHVILLE, Tenn . (Tuesday
FOR IMMEDIATE DISTRIBUTION CUMBERLAND PHARMACEUTICALS AND GLORIA PHARMACEUTICALS ANNOUNCE JOINT RESEARCH & DEVELOPMENT INVESTMENT NASHVILLE, Tenn. (Tuesday, May 6, 2014) - Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and China's Gloria Pharmaceuticals Co. (SHE: 002437) announ
Read more →CPIXCaldolor® Pediatric Pain Study Results To Be Presented At The Pediatric Anesthesiology 2014 Conference
NASHVILLE, Tenn., March 7, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data from a recent study evaluating the efficacy and safety of Caldolor® (ibuprofen) Injection will be presented at the Pediatric Anesthesiology 2014 conference in
Read more →CPIXan inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marke
CUMBERLAND PHARMACEUTICALS ACQUIRES VAPRISOL from Astellas Pharma US, Inc Nashville, Tennessee, (Monday, March 3, 2014) -Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol from Astellas Pharma US, Inc. Vaprisol is a patented, prescription
Read more →CPIXCumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results
NASHVILLE, Tenn., March 4, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently anno
Read more →CPIXCumberland Pharmaceuticals Acquires Vaprisol® from Astellas Pharma US, Inc.
NASHVILLE, Tenn., March 3, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced the acquisition of Vaprisol® from Astellas Pharma US, Inc. Vaprisol® is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients wi
Read more →CPIXCumberland Pharmaceuticals To Announce 2013 Year-End Financial Results On March 4, 2014
NASHVILLE, Tenn., Feb. 27, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release 2013 year-end financial results after the market closes on Tuesday, March 4, 2014. A conference call and live Internet webcast will be held on Tuesda
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter Financial Results
NASHVILLE, Tenn., Nov. 5, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results. Net Revenue: For the three months ended Se
Read more →CPIXQ3 2013 - ex 99.1 earnings release CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS - Omeclamox-Pak introduced as fourth commercial product NASHVILLE, TN (Tuesday
CUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS - Omeclamox-Pak introduced as fourth commercial product NASHVILLE, TN (Tuesday, November 5, 2013) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute c
Read more →CPIXCumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
NASHVILLE, Tenn., Oct. 29, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its third quarter 2013 results after the market closes on Tuesday, November 5, 2013. A conference call and live Internet webcast will be held on Tues
Read more →CPIXCumberland Pharmaceuticals And Pernix Therapeutics Enter Into Exclusive Agreement To Promote Omeclamox-Pak®
NASHVILLE, Tenn. and THE WOODLANDS, Texas, Oct. 28, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) and Pernix Therapeutics, LLC (NYSE: PTX) today announced an agreement for the promotion of Omeclamox-Pak covering the United States. Omeclamox-Pak® is a branded
Read more →CPIXCaldolor® Studies to be Presented at the Annual Meeting of the American Society of Anesthesiologists
NASHVILLE, Tenn., Oct. 10, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) today announced that data from three recent studies evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection will be presented at the Annual Meeting of the American Society
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter Financial Results
NASHVILLE, Tenn., Aug. 6, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2013 financial results. Net Revenue: For the three months ended J
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2013 Financial Results On August 6, 2013
NASHVILLE, Tenn., July 29, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its second quarter 2013 results after the market closes on Tuesday, August 6, 2013. A conference call and live Internet webcast will be held on Tuesd
Read more →CPIXCumberland Pharmaceuticals Reports FDA Approval For Updated Acetadote® Labeling
NASHVILLE, Tenn., June 10, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Acetadote (acetylcysteine) Injection. The new labeling revises the product's indicatio
Read more →CPIXCumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
NASHVILLE, Tenn., May 15, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Healthcare Co
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter Financial Results
NASHVILLE, Tenn., May 2, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2013 financial results. Net Revenue: For the three months ended Mar
Read more →CPIXCumberland Pharmaceuticals To Announce First Quarter 2013 Financial Results On May 2, 2013
NASHVILLE, Tenn., April 25, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its first quarter 2013 results after the market closes on Thursday, May 2, 2013. A conference call and live Internet webcast will be held on Thursda
Read more →CPIXCumberland Pharmaceuticals Reports 2012 Annual Financial Results
NASHVILLE, Tenn., Feb. 28, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2012 financial results. Net Revenue: For the three mo
Read more →CPIXCumberland Pharmaceuticals Licenses Caldolor® (ibuprofen) Injection To Sandor Medicaids Pvt. Ltd. For Commercialization In India
NASHVILLE, Tenn., Feb. 21, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has entered into an exclusive agreement with Sandor Medicaids Pvt. Ltd., an India-based pharmaceutical company, for the commercialization of Caldolor® (ibuprofen
Read more →CPIXCaldolor® Reduces Pain And Fever In Adult Patients
NASHVILLE, Tenn., Feb. 19, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced top-line results from two registry studies evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection administered over a shortened infusion time in treating
Read more →CPIXCumberland Pharmaceuticals To Announce 2012 Year End Financial Results On February 28, 2013
NASHVILLE, Tenn., Feb. 14, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release 2012 year-end financial results after the market closes on Thursday, February 28, 2013. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
NASHVILLE, Tenn., Jan. 29, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced it has entered into an exclusive agreement with Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the registration and commercialization of Caldolor® (ibu
Read more →CPIXCumberland Receives Second Acetadote® Patent Notice of Allowance
NASHVILLE, Tenn., Nov. 7, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.(NASDAQ: CPIX) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a second patent relating to its new formulation of Acetadote® (acetylcyst
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
NASHVILLE, Tenn., Nov. 1, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced third quarter 2012 financial results. Net Revenues: For the three months
Read more →CPIXCumberland Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 1, 2012
NASHVILLE, Tenn., Oct. 18, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2012 results after the market closes on Thursday, November 1, 2012. A conference call and live Internet webcast will be held on Thursda
Read more →CPIXCaldolor® Reduces Narcotic Doses In Pediatric Pain Patients
NASHVILLE, Tenn., Sept. 19, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced top-line results from a clinical pediatric pain study evaluating the safety and analgesic efficacy of Caldolor® (ibuprofen) Injection in treating pain in tonsillectomy
Read more →CPIXCumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
NASHVILLE, Tenn., Sept. 6, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Life Science
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
NASHVILLE, Tenn., Aug. 2, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced second quarter 2012 financial results. Net Revenues: For the three month
Read more →CPIXCumberland Pharmaceuticals To Announce Second Quarter 2012 Financial Results On August 2, 2012
NASHVILLE, Tenn., July 12, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its second quarter 2012 results after the market closes on Thursday, August 2, 2012. A conference call and live Internet webcast will be held on Thur
Read more →CPIXCumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
NASHVILLE, Tenn., June 13, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the Wells Fargo Securities
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
NASHVILLE, Tenn., May 3, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced first quarter 2012 financial results. Net Revenues: For the three months
Read more →CPIXCumberland Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 3, 2012
NASHVILLE, Tenn., April 12, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its first quarter 2012 results after the market closes on Thursday, May 3, 2012. A conference call and live Internet webcast will be held on Thursda
Read more →CPIXCumberland Pharmaceuticals to Present at Needham Life Sciences Conference in New York on April 3, 2012
NASHVILLE, Tenn., March 27, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the Needham Li
Read more →CPIXCumberland Pharmaceuticals Signs Exclusive Licensing Agreement for China
NASHVILLE, Tenn., Feb. 28, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced it has entered into an exclusive agreement with China's Harbin Gloria Pharmaceuticals Co., Ltd. (SHE: 002437)for the commercialization of Acetadote® (acetylcysteine), it
Read more →CPIXCumberland Pharmaceuticals to Announce 2011 Year End Financial Results on February 29, 2012
NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release 2011 year-end financial results after the market closes on Wednesday, February 29, 2012. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Receives Acetadote® Patent Notice of Allowance
NASHVILLE, Tenn., Feb. 8, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office relating to its new formulation of Acetadote® (acetylcysteine) Injection, wh
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
NASHVILLE, Tenn., Nov. 3, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced third quarter 2011 financial results. Net Revenue: For the three months
Read more →CPIXCumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloitte
NASHVILLE, Tenn., Oct. 20, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has been placed on Deloitte's 2011 Technology Fast 500™ list, an annual ranking of the fastest growing technology, media, telecommunications, life sciences and c
Read more →CPIXCumberland Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 3, 2011
NASHVILLE, Tenn., Oct. 13, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release third quarter 2011 financial results after the market closes on Thursday, November 3, 2011. A conference call and live Internet webcast will be held
Read more →CPIXCumberland Pharmaceuticals Appoints Rick S. Greene Chief Financial Officer
NASHVILLE, Tenn., Oct. 12, 2011 Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Rick S. Greene, a long-time financial advisor to the Company, has been appointed Ch
Read more →CPIXCumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference In New York
NASHVILLE, Tenn., Aug. 31, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Life Science
Read more →CPIXCumberland Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference in Boston
NASHVILLE, Tenn., Aug. 25, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the Stifel Nicolaus 2011 He
Read more →CPIXCumberland Pharmaceuticals Inks New Bank Financing Deal With Bank of America
NASHVILLE, Tenn., Aug. 4, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that it has executed a new senior credit agreement with Bank of America. Pursuant to the new agreement, the Company has increased its revolving line of credit to $10 mill
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
NASHVILLE, Tenn., Aug. 4, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced second quarter 2011 financial results. Net Revenue: For the three months
Read more →CPIXCumberland Pharmaceuticals to Present at the 2011 Wells Fargo Securities Healthcare Conference in Boston
NASHVILLE, Tenn., June 7, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the Wells Fargo Securities H
Read more →CPIXCaldolor® Clinical Study in Hospitalized Burn Patients Published in Journal of Burn Care & Research
NASHVILLE, Tenn., May 16, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that results from a clinical study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating fever and pain in hospitalized burn patients was publ
Read more →CPIXCumberland Pharmaceuticals to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London
NASHVILLE, Tenn., May 11, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the 2011 UBS Global Specialt
Read more →CPIXCumberland Pharmaceuticals Reports First Quarter 2011 Financial Results
NASHVILLE, Tenn., May 4, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced first quarter 2011 financial results. Net Revenue: For the three months e
Read more →CPIXCumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
NASHVILLE, Tenn., April 22, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release first quarter 2011 financial results after the market closes on Wednesday, May 4, 2011. A conference call and live Internet webcast will be held on
Read more →CPIXCumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
NASHVILLE, Tenn., April 19, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroba
Read more →CPIXCumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
NASHVILLE, Tenn., April 4, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Rick S. Greene, a long-time financial advisor to the Company, has b
Read more →CPIXNew Acetadote® Formulation Now Available in the U.S.
NASHVILLE, Tenn., March 22, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that it has completed the U.S. launch of its new formulation of Acetadote® (acetylcysteine) Injection, the Company's product used to treat acetaminophen poisoning. The
Read more →CPIXCumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
NASHVILLE, Tenn., March 8, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced fourth quarter and full year 2010 financial results. Net Revenue: For t
Read more →CPIXAnesthesiologists Use Caldolor® To Provide Preemptive Pain Control for Surgical Patients at U.S. Medical Centers
NASHVILLE, Tenn., March 2, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that Caldolor® (ibuprofen) Injection is being used by anesthesiologists in a growing number of hospitals and surgery centers to provide preemptive analgesia for surgical
Read more →CPIXCumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
NASHVILLE, Tenn., Feb. 24, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced that it has appointed pharmaceutical industry veteran Tan Cheow Choo
Read more →CPIXCumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
NASHVILLE, Tenn., Feb. 17, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release 2010 financial results after the market closes on Tuesday, March 8, 2011. A conference call and live Internet webcast will be held on Tuesday, March
Read more →CPIXCaldolor® Rapid Infusion Shown to be Safe and Well Tolerated in Newly Published Clinical Study
NASHVILLE, Tenn., Feb. 15, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data from a clinical trial evaluating the pharmacokinetics, safety and tolerability of a rapid infusion of Caldolor® (ibuprofen) Injection compared to
Read more →CPIXNewly Published Data Demonstrates Caldolor® Significantly Reduces Pain and Morphine Use in Post-Operative Patients
NASHVILLE, Tenn., Jan. 27, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating post-operative pain in hospitalized patients. A Phase III study
Read more →CPIXCumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
NASHVILLE, Tenn., Jan. 13, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for a new formulation of Acetadote® (acetylcysteine) Injection, the Company's product used
Read more →CPIXCumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
NASHVILLE, Tenn., Jan. 6, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is pleased to announce the addition of Joey Jacobs to its Board of Directors. A healthcare veteran with more than 30 years of industry experience, Mr. Jacobs is the former Chairman, Pre
Read more →CPIXCumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
NASHVILLE, Tenn., Dec. 30, 2010 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has implemented a recall of 6 lots of Acetadote® (acetylcysteine) Injection, the Company's injectable treatment to prevent or lessen liver injury after ingestion
Read more →CPIXFDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
NASHVILLE, Tenn., Dec. 22, 2010 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental new drug application (sNDA) for Acetadote® (a
Read more →CPIXNewly Published Data Shows Kristalose Preferred by 77% More Patients Compared to Liquid Lactulose
NASHVILLE, Tenn., Dec. 1, 2010 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of a patient preference study evaluating Kristalose® (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, co
Read more →CPIXCumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
NASHVILLE, Tenn., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced financial results for the third quarter ending September 3
Read more →CPIXCumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010
NASHVILLE, Tenn., Oct. 28 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release third quarter 2010 financial results after the market closes on Thursday, November 11, 2010. A conference call and live Internet webcast will be
Read more →CPIXCumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
NASHVILLE, Tenn. and SYDNEY, Oct. 14 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially availa
Read more →CPIXNewly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
NASHVILLE, Tenn., Oct. 7 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the
Read more →CPIXFIRST AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AGREEMENT THIS FIRST AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AGREEMENT (this Amendment ), dated as of
FOURTH AMENDED AND RESTATED LOAN AGREEMENT THIS FIRST AMENDMENT TO FOURTH AMENDED AND RESTATED LOAN AGREEMENT (this Amendment ), dated as of February 11, 2010, is made and entered into on the terms and conditions hereinafter set forth, by and between CUMBERLAND PHARMACEUTICALS
Read more →CPIXCaldolor® (ibuprofen) Injection Gaining Approval on Formulary at U.S. Medical Centers
NASHVILLE, Tenn., Sept. 23 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that Caldolor® (ibuprofen) Injection is gaining momentum and being approved for use in a growing number of medical facilities across the country. Several key U.S. hospitals,
Read more →CPIXCumberland Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference in Boston
NASHVILLE, Tenn., Sept. 8 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the Stifel Nicolaus 2010 Healthca
Read more →CPIXPre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
NASHVILLE, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of new data supporting the safety and efficacy of Caldolor® (ibuprofen) Injection in pre and post-operative orthopedic surgery patients. The study, w
Read more →CPIXCumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
NASHVILLE, Tenn., Aug. 20 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the U.S. Food and Drug Administration (FDA) has extended its review of the supplemental new drug application (sNDA) for the use of Acetadote® (acetylcysteine) Inject
Read more →CPIXCumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
NASHVILLE, Tenn., Aug. 16 /PRNewswire-FirstCall/ --- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010,
Read more →Competitive Position
How CPIX ranks across every disease it competes inCompetitive Position is a premium feature
See how CPIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial